FULC – Fulcrum Therapeutics Inc
Float Short %
7.43
Margin Of Safety %
Put/Call OI Ratio
0.63
EPS Next Q Diff
0.01
EPS Last/This Y
-1.03
EPS This/Next Y
-0.04
Price
12.99
Target Price
17.56
Analyst Recom
1.56
Performance Q
79.42
Relative Volume
37.05
Beta
3.21
Ticker: FULC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | FULC | 7.68 | 0.41 | 0.00 | 15106 |
| 2025-11-11 | FULC | 8.14 | 0.42 | 0.00 | 14926 |
| 2025-11-12 | FULC | 8.36 | 0.35 | 0.00 | 17112 |
| 2025-11-13 | FULC | 8.76 | 0.34 | 0.00 | 17436 |
| 2025-11-14 | FULC | 8.64 | 0.33 | 0.00 | 17832 |
| 2025-11-17 | FULC | 9.65 | 0.31 | 0.01 | 18590 |
| 2025-11-18 | FULC | 9.75 | 0.31 | 0.14 | 18539 |
| 2025-11-19 | FULC | 11.52 | 0.31 | 1.59 | 18562 |
| 2025-11-20 | FULC | 11.03 | 0.38 | 0.01 | 19699 |
| 2025-11-21 | FULC | 11.31 | 0.37 | 0.07 | 20037 |
| 2025-11-24 | FULC | 11.74 | 0.32 | 5.28 | 18396 |
| 2025-11-25 | FULC | 11.53 | 0.37 | 14.63 | 19094 |
| 2025-11-26 | FULC | 11.3 | 0.40 | 0.00 | 19542 |
| 2025-12-01 | FULC | 9.85 | 0.70 | 5.65 | 23737 |
| 2025-12-02 | FULC | 8.95 | 0.57 | 0.01 | 21733 |
| 2025-12-03 | FULC | 9.05 | 0.62 | 0.91 | 22601 |
| 2025-12-04 | FULC | 8.75 | 0.62 | 0.22 | 22757 |
| 2025-12-05 | FULC | 8.89 | 0.63 | 0.51 | 22016 |
| 2025-12-08 | FULC | 11.8 | 0.63 | 0.60 | 22811 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | FULC | 7.67 | -1.6 | - | -1.18 |
| 2025-11-11 | FULC | 8.15 | -1.6 | - | -1.18 |
| 2025-11-12 | FULC | 8.38 | -1.6 | - | -1.18 |
| 2025-11-13 | FULC | 8.77 | -1.6 | - | -1.18 |
| 2025-11-14 | FULC | 8.65 | -1.6 | - | -1.18 |
| 2025-11-17 | FULC | 9.64 | -1.6 | - | -1.18 |
| 2025-11-18 | FULC | 9.75 | -1.6 | - | -1.18 |
| 2025-11-19 | FULC | 11.51 | -1.6 | - | -1.18 |
| 2025-11-20 | FULC | 11.04 | -1.6 | - | -1.19 |
| 2025-11-21 | FULC | 11.31 | -3.6 | - | -1.19 |
| 2025-11-24 | FULC | 11.73 | -3.6 | - | -1.19 |
| 2025-11-25 | FULC | 11.54 | -3.6 | - | -1.19 |
| 2025-11-26 | FULC | 11.31 | -3.6 | - | -1.19 |
| 2025-12-01 | FULC | 9.85 | -3.2 | - | -1.19 |
| 2025-12-02 | FULC | 8.95 | -3.2 | - | -1.19 |
| 2025-12-03 | FULC | 9.06 | -3.2 | - | -1.19 |
| 2025-12-04 | FULC | 8.76 | -3.2 | - | -1.19 |
| 2025-12-05 | FULC | 8.90 | -3.2 | - | -1.19 |
| 2025-12-08 | FULC | 12.99 | -3.2 | - | -1.19 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | FULC | 0.00 | 1.26 | 7.40 |
| 2025-11-11 | FULC | 0.00 | 1.26 | 7.40 |
| 2025-11-12 | FULC | 0.00 | 1.26 | 7.35 |
| 2025-11-13 | FULC | 0.00 | 1.26 | 7.35 |
| 2025-11-14 | FULC | 0.00 | 1.26 | 7.35 |
| 2025-11-17 | FULC | 0.00 | 2.63 | 7.35 |
| 2025-11-18 | FULC | 0.00 | 2.63 | 7.35 |
| 2025-11-19 | FULC | 0.00 | 2.63 | 7.35 |
| 2025-11-20 | FULC | 0.00 | 2.63 | 7.35 |
| 2025-11-21 | FULC | -0.24 | 2.63 | 7.35 |
| 2025-11-24 | FULC | -0.24 | -2.43 | 7.35 |
| 2025-11-25 | FULC | -0.24 | -2.43 | 7.35 |
| 2025-11-26 | FULC | -0.24 | -2.43 | 7.43 |
| 2025-12-01 | FULC | -0.24 | -2.38 | 7.43 |
| 2025-12-02 | FULC | -0.24 | -2.38 | 7.43 |
| 2025-12-03 | FULC | -0.24 | -2.38 | 7.43 |
| 2025-12-04 | FULC | -0.24 | -2.38 | 7.43 |
| 2025-12-05 | FULC | -0.24 | -2.38 | 7.43 |
| 2025-12-08 | FULC | -0.24 | -2.39 | 7.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.31
Avg. EPS Est. Current Quarter
-0.32
Avg. EPS Est. Next Quarter
-0.3
Insider Transactions
-0.24
Institutional Transactions
-2.39
Beta
3.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
18
Sentiment Score
17
Actual DrawDown %
60.8
Max Drawdown 5-Year %
-92.7
Target Price
17.56
P/E
Forward P/E
PEG
P/S
P/B
3.54
P/Free Cash Flow
EPS
-1.18
Average EPS Est. Cur. Y
-1.19
EPS Next Y. (Est.)
-1.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
37.05
Return on Equity vs Sector %
-62.7
Return on Equity vs Industry %
-47.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Fulcrum Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 45
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today
news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance
stock history FULC – Fulcrum Therapeutics Inc invest stock market
stock prices FULC premarket after hours
ticker FULC fair value insiders trading